The goal of this clinical trial is to compare the efficacy and safety of intravesical Botulinum Toxin A versus intravesical Platelet-Rich Plasma (PRP) in adults with refractory overactive bladder who have not responded adequately to conventional medical treatment. The main questions it aims to answer are:
* Whether intravesical PRP is as effective as intravesical Botulinum Toxin A in improving overactive bladder symptoms.
* Whether intravesical PRP has a better safety profile and lower incidence of adverse events during the 2-year follow-up period.
Researchers will compare participants receiving intravesical Botulinum Toxin A with those receiving intravesical PRP to determine differences in symptom improvement, quality of life, urodynamic outcomes, and treatment-related adverse events.
Participants will:
* Receive either intravesical Botulinum Toxin A injection or intravesical Platelet-Rich Plasma injection.
* Undergo baseline clinical assessment, symptom evaluation, and urodynamic studies as indicated.
* Attend scheduled follow-up visits over a 2-year period.
* Complete validated questionnaires assessing overactive bladder symptoms and quality of life.
* Be monitored for treatment efficacy and any adverse events throughout the study.